Angelo Di Leo
Angelo Di Leo
Hospital of Prato
Verified email at uslcentro.toscana.it - Homepage
TitleCited byYear
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
21342013
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...
Annals of oncology 26 (8), 1533-1546, 2015
11202015
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition …
S Loi, N Sirtaine, F Piette, R Salgado, G Viale, F Van Eenoo, G Rouas, ...
J Clin Oncol 31 (7), 860-867, 2013
8602013
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, ...
J Clin Oncol 28 (30), 4594-4600, 2010
5362010
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, ...
J Clin Oncol 28 (30), 4594-4600, 2010
5362010
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
A Di Leo, HL Gomez, Z Aziz, Z Zvirbule, J Bines, MC Arbushites, ...
Journal of Clinical Oncology 26 (34), 5544, 2008
4472008
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples
M Tanner, D Gancberg, A Di Leo, D Larsimont, G Rouas, MJ Piccart, ...
The American journal of pathology 157 (5), 1467-1472, 2000
4332000
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
D Gancberg, A Di Leo, F Cardoso, G Rouas, M Pedrocchi, M Paesmans, ...
Annals of Oncology 13 (7), 1036-1043, 2002
3502002
HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based …
A Di Leo, D Gancberg, D Larsimont, M Tanner, T Jarvinen, G Rouas, ...
Clinical Cancer Research 8 (5), 1107-1116, 2002
3492002
Dissecting the heterogeneity of triple-negative breast cancer
O Metzger-Filho, A Tutt, E De Azambuja, KS Saini, G Viale, S Loi, ...
Journal of clinical oncology 30 (15), 1879-1887, 2012
3322012
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, HJ Burstein, E P Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
3252017
Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: a study by the Italian Trials in Medical Oncology Group
M Di Bartolomeo, E Bajetta, R Buzzoni, L Mariani, C Carnaghi, L Somma, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 1996
3221996
1st International consensus guidelines for advanced breast cancer (ABC 1)
F Cardoso, A Costa, L Norton, D Cameron, T Cufer, L Fallowfield, ...
The Breast 21 (3), 242-252, 2012
3032012
MONARCH 3: abemaciclib as initial therapy for advanced breast cancer
MP Goetz, M Toi, M Campone, J Sohn, S Paluch-Shimon, J Huober, ...
Journal of Clinical Oncology, 2017
2962017
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement
S Guiu, S Michiels, F Andre, J Cortes, C Denkert, A Di Leo, BT Hennessy, ...
Annals of oncology 23 (12), 2997-3006, 2012
2452012
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
EJ Jung, L Santarpia, J Kim, FJ Esteva, E Moretti, AU Buzdar, A Di Leo, ...
Cancer 118 (10), 2603-2614, 2012
2342012
Metabolomics: available results, current research projects in breast cancer, and future applications
WM Claudino, A Quattrone, L Biganzoli, M Pestrin, I Bertini, A Di Leo
Journal of clinical oncology 25 (19), 2840-2846, 2007
2202007
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients
M Pestrin, S Bessi, F Galardi, M Truglia, A Biggeri, C Biagioni, ...
Breast cancer research and treatment 118 (3), 523, 2009
2112009
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer
MJ Piccart, A Di Leo, M Beauduin, A Vindevoghel, J Michel, C Focan, ...
Journal of clinical oncology 19 (12), 3103-3110, 2001
2052001
Management of triple negative breast cancer
C Oakman, G Viale, A Di Leo
The Breast 19 (5), 312-321, 2010
1982010
The system can't perform the operation now. Try again later.
Articles 1–20